Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Neurologists appeal to health secretary over withdrawal of drug for MS patients.

Laurance J.

BMJ. 2012 Nov 2;345:e7449. doi: 10.1136/bmj.e7449. No abstract available.

PMID:
23125160
2.

Natalizumab for relapsing remitting multiple sclerosis.

Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007621. doi: 10.1002/14651858.CD007621.pub2. Review.

PMID:
21975773
3.

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Hersh CM, Cohen JA.

Immunotherapy. 2014;6(3):249-59. doi: 10.2217/imt.14.7. Review.

PMID:
24762071
4.

Daclizumab for relapsing remitting multiple sclerosis.

Liu J, Wang L, Zhan SY, Xia Y.

Cochrane Database Syst Rev. 2012 Apr 18;(4):CD008127. doi: 10.1002/14651858.CD008127.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;(12):CD008127.

PMID:
22513956
5.

Alemtuzumab for multiple sclerosis.

Riera R, Porfírio GJ, Torloni MR.

Cochrane Database Syst Rev. 2016 Apr 15;4:CD011203. doi: 10.1002/14651858.CD011203.pub2. Review.

PMID:
27082500
6.

Natalizumab for relapsing-remitting multiple sclerosis.

Horga A, Tintoré M.

Neurologia. 2011 Jul-Aug;26(6):357-68. doi: 10.1016/j.nrl.2010.10.004. Epub 2010 Dec 28. Review. English, Spanish.

7.

Daclizumab for relapsing remitting multiple sclerosis.

Liu J, Wang LN, Zhan S, Xia Y.

Cochrane Database Syst Rev. 2013 Dec 23;(12):CD008127. doi: 10.1002/14651858.CD008127.pub4. Review.

PMID:
24363032
8.

▼ Daclizumab for MS.

[No authors listed]

Drug Ther Bull. 2017 Feb;55(2):18-21. doi: 10.1136/dtb.2017.2.0454. Review. Erratum in: Drug Ther Bull. 2018 Mar 8;:.

PMID:
28183723
9.

New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis.

Fox EJ, Rhoades RW.

Curr Opin Neurol. 2012 Feb;25 Suppl:S11-9. doi: 10.1097/01.wco.0000413320.94715.e9. Review.

PMID:
22398660
10.

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.

Jones DE, Goldman MD.

Expert Rev Clin Immunol. 2014 Oct;10(10):1281-91. doi: 10.1586/1744666X.2014.951332. Epub 2014 Aug 22. Review.

PMID:
25148422
11.

Natalizumab: state of the art and open questions.

Comi G.

Neurol Sci. 2011 Jan;31 Suppl 3:313-5. doi: 10.1007/s10072-010-0430-2. Review. No abstract available.

PMID:
21107875
12.

Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.

Martin R.

Clin Immunol. 2012 Jan;142(1):9-14. doi: 10.1016/j.clim.2011.10.008. Epub 2011 Nov 9. Review.

PMID:
22284868
13.

An update on new and emerging therapies for relapsing-remitting multiple sclerosis.

Weinstock-Guttman B.

Am J Manag Care. 2013 Nov;19(17 Suppl):s343-54. Review.

14.

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.

Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui MK, Taneja A, Deniz B.

Curr Med Res Opin. 2014 Apr;30(4):613-27. doi: 10.1185/03007995.2013.863755. Epub 2013 Nov 26. Review.

PMID:
24195574
15.

Daclizumab for relapsing remitting multiple sclerosis.

Liu J, Wang L, Zhan S, Tan J, Xia Y.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD008127. doi: 10.1002/14651858.CD008127.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD008127.

PMID:
20556791
16.

Emerging injectable therapies for multiple sclerosis.

Oh J, Calabresi PA.

Lancet Neurol. 2013 Nov;12(11):1115-26. doi: 10.1016/S1474-4422(13)70192-3. Epub 2013 Oct 1. Review.

PMID:
24090587
17.

Rituximab for relapsing-remitting multiple sclerosis.

He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H.

Cochrane Database Syst Rev. 2013 Dec 6;(12):CD009130. doi: 10.1002/14651858.CD009130.pub3. Review.

PMID:
24310855
18.

Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis.

Fox EJ.

Expert Rev Neurother. 2010 Dec;10(12):1789-97. doi: 10.1586/ern.10.135. Review.

PMID:
21091310
19.

Update on multiple sclerosis treatments.

Bridel C, Lalive PH.

Swiss Med Wkly. 2014 Sep 23;144:w14012. doi: 10.4414/smw.2014.14012. eCollection 2014. Review.

20.

Fingolimod for relapsing-remitting multiple sclerosis.

La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G.

Cochrane Database Syst Rev. 2016 Apr 19;4:CD009371. doi: 10.1002/14651858.CD009371.pub2. Review.

PMID:
27091121

Supplemental Content

Support Center